Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on November 18.Don't Miss our ...

We recently published a list of 10 Best Multibagger Stocks To Buy Heading into 2025. In this article, we are going to take a ...

Larimar Therapeutics (NASDAQ:LRMR – Get Free Report)‘s stock had its “outperform” rating reissued by equities research analysts at William Blair in a research report issued to clients and investors on ...

Larimar Therapeutics, Inc. (Nasdaq: LRMR) recently presented encouraging data from its studies on nomlabofusp at the ...

周二，H.C. Wainwright在Larimar Therapeutics (NASDAQ:LRMR)在国际共济失调研究大会（ICAR）上展示数据后，重申了对该公司的买入评级和15.00美元的目标价。这些数据涉及Larimar的主要产品候选nomlabofusp，该产品正在开发作为弗里德赖希共济失调（FA）的潜在治疗方法，FA是一种目前尚无治愈方法的罕见且进行性的神经退行性运动障碍。

In this article, we are going to take a look at where Larimar Therapeutics, Inc. (NASDAQ:LRMR) stands against other best multibagger stocks. November has been an eventful month so far for the ...

Larimar Therapeutics (LRMR) presented data from the company’s Phase 1 studies and the Phase 2 dose exploration study of nomlabofusp in Friedreich’s ataxia, or FA, at the International Congress for ...

HC Wainwright & Co.：重申Larimar Therapeutics(LRMR.US)评级，由买入调整至买入评级, 目标价由15.00美元调整至15.00美元。 Larimar Therapeutics（LRMR.US）公司简介 ...

宾夕法尼亚州巴拉辛威德 - 生物技术公司Larimar Therapeutics, Inc. (NASDAQ: LRMR)上周在伦敦举行的国际共济失调研究大会上报告了其用于治疗弗里德赖希共济失调(FA)的实验性药物nomlabofusp的进展。根据公司的第1期和第2期研究数据，nomlabofusp与成年FA患者的基因表达修改、脂质谱改善和frataxin水平增加有关。 这些研究包括61名成年FA ...

Larimar Therapeutics (LRMR) presented data from the company’s Phase 1 studies and the Phase 2 dose exploration study of nomlabofusp in Friedreich’s ataxia, or FA, at the International Congress ...